NCT00227409|Completed
Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency
Long-Term Repeated Lead Chelation Therapy in Non-Diabetic Patients With Chronic Renal Insufficiency and High-Normal Body Lead Burden
Loading search results
Long-Term Repeated Lead Chelation Therapy in Non-Diabetic Patients With Chronic Renal Insufficiency and High-Normal Body Lead Burden
Sponsor study identifier
Secondary identifiers
interventional
N/A
1 country
1
Study Start
November 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
October 2005
Date type not reportedThis date has not been verified as actual or estimated.
Previous study showed repeated lead chelation therapy significant reduced progressive renal insufficiency in patients with chronic renal diseases and high-normal body lead burden in a placebo-controlled, randomized, 2-year clinical trial, even factors that influence progression, such as blood pressure, the presence or absence of hyperlipidemia, and urinary protein excretion were well controlled.Since relative small sample size and short duration of follow-up were noted in the previous study, whether repeated lead chelation therapy could long-term retard the progression of renal insufficiency remains unknown. Hence, we conducted a 51-month placebo-controlled clinical trial to assess the long-term effect of repeated chelation in progressive renal insufficiency of patients with high-normal body lead burden.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2005
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2001
Date type not reportedThis date has not been verified as actual or estimated.
September 26, 2005
Actual (reported)September 28, 2005
Actual (reported)October 2005
Date type not reportedThis date has not been verified as actual or estimated.
The primary end point was an increase in serum creatinine to 2 times the base-line value or the need for dialysis.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Chang Gung Memorial Hospital
Taipei, Taiwan, 105, China
Ja-Liang Lin, MD
Division of Nephrology, Chang Gung Memorial Hospital
First Submitted
September 26, 2005
First Posted
September 28, 2005
Study Start
November 2001
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
October 2005
Date type not reportedContact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
October 18, 2006
Record last verified: 2005-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: